Cargando…

Are the current recommendations for the use of aspirin in primary prevention of cardiovascular disease applicable in low-income countries?

Although evidence has accumulated that long-term aspirin therapy is beneficial in secondary prevention of cardiovascular disease (CVD), a lot of controversies persist regarding the benefit of aspirin use in primary prevention of CVD. In low-income countries (LIC) specifically, the decision to prescr...

Descripción completa

Detalles Bibliográficos
Autores principales: Noubiap, Jean Jacques N, Nansseu, Jobert Richie N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556041/
https://www.ncbi.nlm.nih.gov/pubmed/26345154
http://dx.doi.org/10.2147/VHRM.S87398
_version_ 1782388294059819008
author Noubiap, Jean Jacques N
Nansseu, Jobert Richie N
author_facet Noubiap, Jean Jacques N
Nansseu, Jobert Richie N
author_sort Noubiap, Jean Jacques N
collection PubMed
description Although evidence has accumulated that long-term aspirin therapy is beneficial in secondary prevention of cardiovascular disease (CVD), a lot of controversies persist regarding the benefit of aspirin use in primary prevention of CVD. In low-income countries (LIC) specifically, the decision to prescribe aspirin for primary CVD prevention is more problematic, as there is a dearth of evidence in this regard. Aspirin has been shown to have relative beneficial effects in preventing a first myocardial infarction, but not stroke. However, as stroke is the prevailing CVD in many LIC, especially in Africa, the benefit of aspirin in these settings is therefore questionable. Indeed, there is no published trial that has evaluated the benefits and risks of continuous aspirin therapy in populations of LIC. Furthermore, though cardiovascular risk assessment is crucial in decision-making for the use of aspirin in primary prevention of CVD, there are no risk assessment tools that have been validated in African populations. Studies are urgently warranted, to determine the usefulness of aspirin in primary prevention of CVD in low-income settings where the drug is highly available and affordable, as CVD is becoming the leading cause of deaths in LIC.
format Online
Article
Text
id pubmed-4556041
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-45560412015-09-04 Are the current recommendations for the use of aspirin in primary prevention of cardiovascular disease applicable in low-income countries? Noubiap, Jean Jacques N Nansseu, Jobert Richie N Vasc Health Risk Manag Commentary Although evidence has accumulated that long-term aspirin therapy is beneficial in secondary prevention of cardiovascular disease (CVD), a lot of controversies persist regarding the benefit of aspirin use in primary prevention of CVD. In low-income countries (LIC) specifically, the decision to prescribe aspirin for primary CVD prevention is more problematic, as there is a dearth of evidence in this regard. Aspirin has been shown to have relative beneficial effects in preventing a first myocardial infarction, but not stroke. However, as stroke is the prevailing CVD in many LIC, especially in Africa, the benefit of aspirin in these settings is therefore questionable. Indeed, there is no published trial that has evaluated the benefits and risks of continuous aspirin therapy in populations of LIC. Furthermore, though cardiovascular risk assessment is crucial in decision-making for the use of aspirin in primary prevention of CVD, there are no risk assessment tools that have been validated in African populations. Studies are urgently warranted, to determine the usefulness of aspirin in primary prevention of CVD in low-income settings where the drug is highly available and affordable, as CVD is becoming the leading cause of deaths in LIC. Dove Medical Press 2015-08-25 /pmc/articles/PMC4556041/ /pubmed/26345154 http://dx.doi.org/10.2147/VHRM.S87398 Text en © 2015 Noubiap and Nansseu. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Commentary
Noubiap, Jean Jacques N
Nansseu, Jobert Richie N
Are the current recommendations for the use of aspirin in primary prevention of cardiovascular disease applicable in low-income countries?
title Are the current recommendations for the use of aspirin in primary prevention of cardiovascular disease applicable in low-income countries?
title_full Are the current recommendations for the use of aspirin in primary prevention of cardiovascular disease applicable in low-income countries?
title_fullStr Are the current recommendations for the use of aspirin in primary prevention of cardiovascular disease applicable in low-income countries?
title_full_unstemmed Are the current recommendations for the use of aspirin in primary prevention of cardiovascular disease applicable in low-income countries?
title_short Are the current recommendations for the use of aspirin in primary prevention of cardiovascular disease applicable in low-income countries?
title_sort are the current recommendations for the use of aspirin in primary prevention of cardiovascular disease applicable in low-income countries?
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556041/
https://www.ncbi.nlm.nih.gov/pubmed/26345154
http://dx.doi.org/10.2147/VHRM.S87398
work_keys_str_mv AT noubiapjeanjacquesn arethecurrentrecommendationsfortheuseofaspirininprimarypreventionofcardiovasculardiseaseapplicableinlowincomecountries
AT nansseujobertrichien arethecurrentrecommendationsfortheuseofaspirininprimarypreventionofcardiovasculardiseaseapplicableinlowincomecountries